• Eli Lilly to acquire Dice Therapeutics for $2.4B

    Eli Lilly plans to acquire Dice Therapeutics — a biopharmaceutical company that develops oral therapeutics for autoimmune diseases — in a deal valued at $2.4 billion. 
  • Louisiana enacts law to protect 340B contract pharmacies

    Louisiana passed a bill that prevents drugmakers from restricting 340B-discounted drugs to safety-net hospitals' contract pharmacies. The law is effective Aug. 1. 
  • Nurses can now certify their jump to pharmacy work

    The Accreditation Council for Medical Affairs on June 20 unveiled the first and only accredited certification for nurses wanting to transition to the biopharmaceutical industry. 
  • Why drug shortages might worsen

    FDA investigators discovered more quality issues at an Intas Pharmaceuticals factory in Ahmedabad, India, which halted some production after a November inspection found a truck full of shredded documents, Bloomberg reported June 15. 
  • 5 deaths partially halt drug trial

    In two days, two Cambridge, Mass.-based pharma companies have paused their cancer drug trials after six patients died. 
  • Michigan drugmaker recalls meds in wrong package

    Major Pharmaceutical/Rugby Laboratories, based in Livonia, Mich., is recalling one lot of an anti-nausea drug because a distributor found it to be mislabeled as the drugmaker's schizophrenia drug.
  • 40% of ulcerative colitis patients in clinical trial reached remission with AbbVie drug

    A 52-week phase 3 clinical trial of Skyrizi, or risankizumab — a drug initially approved to treat Crohn's disease, psoriatic arthritis and psoriasis — was shown to also achieve clinical remission in 40 percent of patients with ulcerative colitis, AbbVie announced June 15. 
  • Preparing for new USP standards: 5 things to know

    On Nov. 1, the new U.S. Pharmacopoeia standards on sterile and nonsterile compounding will be implemented. Here's what leaders need to know about USP 795 and USP 797: 
  • Inflation Reduction Act projected to save cancer patients $7,590 every year

    The Inflation Reduction Act could offer cancer patients annual savings of $7,590 on average, and some patients could save up to $19,296, according to a June 14 report from Patients for Affordable Drugs. 
  • Seattle Children's, drug company pause trial after patient death

    Seattle Children's Hospital paused a sponsored clinical study of a leukemia drug candidate after the first patient to take the medication died, according to the oncology cell-therapy company 2seventy Bio. 
  • Cost Plus Drugs ends plan to sell insulin

    Mark Cuban Cost Plus Drug Co. considered selling insulin but found the price doubled with shipping costs, CEO and co-founder Alex Oshmyansky, MD, PhD, said June 13 at the AHIP conference. 
  • Connecticut pharmacists can now prescribe birth control

    Connecticut Gov. Ned Lamont signed a bill June 13 allowing pharmacists to prescribe birth control without a patient being required to visit a physician. 
  • Pfizer to run out of penicillin solutions in next few months

    Amid a shortage of amoxicillin and penicillin — the two main antibiotics for strep infections, which rose in early 2023 — Pfizer said it has "limited supply and [an] impending stock out situation" for some of its penicillin prefilled syringe products. 
  • 4 ways Sanofi is using AI to power pharma innovations

    Sanofi announced its latest endeavor into AI technologies with the use of an internal app, which company CEO Paul Hudson says is a move to align with its aim to become the "first pharma company powered by artificial intelligence at scale," according to a June 13 news release. 
  • FDA approves 1st pediatric drug for functional constipation

    The FDA approved Ironwood Pharmaceuticals' Linzess (linaclotide) capsules June 12, making it the first pediatric treatment for functional constipation. 
  • Erectile dysfunction gel receives FDA green light

    An over-the-counter topical treatment for men with erectile dysfunction on May 12 was authorized by the FDA for marketing. Futura Medical's Eroxon gel can now be marketed as a de novo medical device.
  • 6 Ozempic updates

    Novo Nordisk's Type 2 diabetes drug Ozempic (semaglutide) shot up in popularity for its off-label use for weight loss. Here are six recent updates on the drug: 
  • Alternative funding programs can spike drug costs, harm patients, advocacy group says

    The Alliance for Patient Access, a national advocacy group, has published a report outlining key ways employer-sponsored health plans can benefit from alternative funding programs at the expense of some patients.
  • Novartis will buy Chinook Therapeutics for $3.5B

    Novartis announced June 12 that it will acquire Chinook Therapeutics, a Seattle-based biopharmaceutical company that develops novel kidney medicines, for a total value of $3.5 billion.
  • Illumina CEO resigns

    Francis deSouza, CEO of San Diego-based biotech company Illumina, stepped down from the role June 11 and will be an adviser through July. 

Featured Whitepapers

Featured Webinars